These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25422080)

  • 1. The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
    Tabolli S; Giannantoni P; Paradisi A; Abeni D
    Br J Dermatol; 2015 Jul; 173(1):256-8. PubMed ID: 25422080
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
    Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
    Wald JM; Klufas DM; Strober BE
    J Drugs Dermatol; 2015 Aug; 14(8):888-92. PubMed ID: 26267735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
    Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
    J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
    Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
    J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
    Marinas JE; Kim WB; Shahbaz A; Qiang JK; Greaves S; Yeung J
    Australas J Dermatol; 2018 Feb; 59(1):e11-e14. PubMed ID: 27858976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C; Marshman G; Grillo M; Stanford T
    Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
    Pinheiro RR; Duarte B; Ferreira A; Cabete J
    Eur J Dermatol; 2018 Feb; 28(1):89-91. PubMed ID: 29400282
    [No Abstract]   [Full Text] [Related]  

  • 13. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.
    Jacobi A; Rustenbach SJ; Augustin M
    Int J Dermatol; 2016 Mar; 55(3):296-302. PubMed ID: 26470689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication adherence among patients with psoriasis on traditional systemic and biologics treatment.
    Hambly R; Kelly A; Gilhooley E; Nic Dhonncha E; Murad A; Hughes R; Lally A; Kirby B
    Br J Dermatol; 2018 Jan; 178(1):e46-e48. PubMed ID: 28762482
    [No Abstract]   [Full Text] [Related]  

  • 15. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
    Nast A; Gisondi P; Ormerod AD; Saiag P; Smith C; Spuls PI; Arenberger P; Bachelez H; Barker J; Dauden E; de Jong EM; Feist E; Jacobs A; Jobling R; Kemény L; Maccarone M; Mrowietz U; Papp KA; Paul C; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Yawalkar N
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2277-94. PubMed ID: 26481193
    [No Abstract]   [Full Text] [Related]  

  • 16. Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis.
    Blauvelt A; Armstrong AW; Krueger GG
    J Drugs Dermatol; 2015 Aug; 14(8):805-12. PubMed ID: 26267724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
    Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
    Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
    Wilsmann-Theis D; Frambach Y; Philipp S; Weyergraf AJ; Jacobi A; Mössner R; Gerdes S
    Dermatology; 2015; 230(2):119-27. PubMed ID: 25661583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.